Healthcare / Medical DevicesShanghai
$109.86
-1.25 (-1.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-54.1M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.0B
P/E
323.1x
↑EV/EBITDA
75.0x
↑ROE
2.8%
↑Gross Margin
58.4%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.5%
FCF CAGR
—
FCF margin
-0.2%
FCF / Net income
-0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $398.4M · net income $23.2M · FCF $-961325.6
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $398.4M | $398.4M | $402.3M | $394.4M | $320.4M |
| Net Income | $23.2M | $23.2M | $36.8M | $47.3M | $41.7M |
| EBITDA | $91.6M | $91.6M | $88.9M | $98.7M | $80.9M |
| EPS | 0.37 | 0.37 | 0.58 | 0.74 | 0.66 |
| Gross Margin | 58.4% | 58.4% | 63.9% | 62.1% | 63.1% |
| Operating Margin | 5.0% | 5.0% | 11.3% | 14.0% | 13.3% |
| Net Margin | 5.8% | 5.8% | 9.1% | 12.0% | 13.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.14 | 0.07 | 0.08 |
| Current Ratio | 2.75 | 2.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-961325.55 | $-961325.55 | $-54.1M | $-75.3M | $-161.9M |
| Returns | |||||
| ROE | 2.8% | 2.8% | 4.5% | 5.8% | 5.3% |
| Valuation | |||||
| P/E | 323.12 | 323.12 | 152.76 | 46.68 | 53.35 |
| EV/EBITDA | 75.05 | 75.05 | 63.18 | 21.30 | 26.37 |
| P/B | 8.40 | 8.40 | 6.92 | 2.72 | 2.85 |
| Growth & Yield | |||||
| Revenue Growth | -1.0% | -1.0% | 2.0% | 23.1% | — |
| EPS Growth | -36.2% | -36.2% | -21.6% | 12.1% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
197.6%
EPS terminal req.
$9.75
Spread vs growth
-233.8%
5Y implied EPS CAGR
99.8%
EPS terminal req.
$11.80
Spread vs growth
-136.1%
10Y implied EPS CAGR
48.3%
EPS terminal req.
$19.00
Spread vs growth
-84.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.7%
Start / end P/E
155.9x → 296.9x
EPS bridge
0.58 → 0.37
Residual
-32.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.